The Economist: Sam Glick On How Covid-19 Is Reshaping Big Pharma

COVID has made the pharmaceutical industry more nimble and innovative, including the area of clinical trials.

Sam Glick of Oliver Wyman, a consultancy, notes that new patient enrolment for clinical trials, which plunged by nearly 80% amid the pandemic, has rebounded as firms have embraced digital tools such as remote monitoring, electronic patient-screening and tele-consultations. 

Read more here.